Good Clinical Response to Erlotinib in a Lung Adenocancer Patient and Grade 3 Skin Rash: A Case Report

[LANGUAGE= "English"] Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase (EGFR-TKI), has been proven to prolong survival in non-small cell lung cancer (NSCLC) patients after...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Clinical Practice & Research 2011-01, Vol.33 (2), p.145
Main Authors: Karaca, Halit, Lale, Ayhan, Dikilitaş, Mustafa, Berk, Veli, Özkan, Metin, Er, Özlem
Format: Article
Language:English
Subjects:
Cancer therapies
Chemotherapy
Epidermal growth factor
Inhibitor drugs
Lung cancer
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[LANGUAGE= "English"] Epidermal growth factor receptor (EGFR) has received a particular attention in lung cancer treatment. Erlotinib, an orally available inhibitor of EGFR tyrosine kinase (EGFR-TKI), has been proven to prolong survival in non-small cell lung cancer (NSCLC) patients after first or second line chemotherapy. Skin rash is the most common adverse event associated with erlotinib treatment and a significant correlation between severity of rash and survival has been found. We report a case of lung adenocancer that we obtain good response together with severe skin rash by erlotinib therapy.
ISSN:2980-2156